
Currently out of the existing stock ratings of Nigel Dally, 73 are a SELL (11.42%), 379 are a HOLD (59.31%), 187 are a BUY (29.26%).
Analyst Nigel Dally, currently employed at MORGAN STANLEY, has had 78.03% of price targets met with an average potential upside of 38.49%, reached in 333 days on average.
Nigel Dally has documented 1,207 price targets and ratings displayed on 24 stocks. The coverage is on Financial Services, Healthcare, Communication Services, Basic Materials sectors.
Most recent stock forecast was given on UNM, Unum Group at 10-Nov-2026.
Analyst best performing recommendations are on ARQT (ARCUTIS BIOTHERAPEUTICS).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS) on 11/13/2023. The price target of $10 was fulfilled within 106 days with a profit of $7.89 (373.93%), with a performance score of 35.28.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 25-Feb-2026
$124
$-3.61 (-2.83%)
$116
5 days ago
(12-Nov-2026)
Sell Since 01-Feb-2024
$116
$-11.61 (-9.10%)
$115
5 days ago
(12-Nov-2026)
Sell Since 04-Dec-2020
$117
$-10.61 (-8.31%)
$107
5 days ago
(12-Nov-2026)
Buy Since 03-Apr-2020
$143
$15.39 (12.06%)
$138
8 days ago
(09-Nov-2026)
4/7 (57.14%)
$18.94 (15.27%)
299
Hold Since 21-Jul-2026
$119
$-8.61 (-6.75%)
$116
1 months 2 days ago
(15-Oct-2026)
3/3 (100%)
$0.95 (0.80%)
17
Which stock is Nigel Dally most bullish on?
Which stock is Nigel Dally most reserved on?
What Year was the first public recommendation made by Nigel Dally?